# Immunogenicity and Safety of Pentaxim™ in an Indian Population

> **NCT00259337** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 226 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Polio
- Pertussis
- Haemophilus Infections

## Interventions

- **BIOLOGICAL:** Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine

## Key facts

- **NCT ID:** NCT00259337
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-04
- **Final completion:** 2008-12
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2012-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259337, "Immunogenicity and Safety of Pentaxim™ in an Indian Population". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00259337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*